N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof

ABSTRACT

N 2  -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof have been found to be effective as pharmaceutical agents for the inhibition and suppression of thrombosis.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation in part of application Ser. No. 671,436 Mar. 29, 1976, which in turn was a divisional of application Ser. No. 622,390 filed Oct. 14, 1975 now abandoned.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to the discovery of certain new and useful N² -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof, which are of especial value in view of their outstanding antithromobotic properties and low toxicities.

2. Description of the Prior Art

In the past, there have been many attempts to obtain new and improved agents for the treatment of thrombosis. The N² -(p-tolysulfonyl)-L-arginine esters have been found to be one type of agent which can be used and these have been found to be effective in dissolving blood clots. (U.S. Pat. No. 3,622,615, issued Nov. 23, 1971)

One family of compounds, which have been found to be particularly useful as highly specific inhibitors of thrombin for the control of thrombosis is the N² -dansyl-L-arginine ester or amide. (Our pending U.S. application Ser. No. 496,939 filed Aug. 13, 1974, now U.S. Pat. No. 3,978,045)

However, there is a continuing need for a highly specific inhibitor on thrombin for the control of thrombosis, which exhibits lower toxicity.

SUMMARY OF THE INVENTION

It has now been discovered that N² -alkoxynaphthalene-sulfonyl-L-argininamides exhibit antithrombotic activity and even lower toxicity levels at the same relative potencies, as compared with the N² -dansyl-L-arginine ester or amide.

The compounds of this invention can be represented by the formula (I): ##STR1## wherein R₁ is naphthyl substituted with at least one C₁ -C₅ alkoxy; R₂ is C₃ -C₁₀ cycloakyl or C₄ -C₁₀ cycloalkylalkyl; R₃ is selected from the group consisting of hydrogen, C₁ -C₁₀ alkyl, C₆ -C₁₀ aryl and C₇ -C₁₂ aralkyl; and n is an integer of 1, 2 or 3.

Also encompassed within this invention are pharmaceutically acceptable salts thereof.

This invention also relates to a method for inhibiting activity and suppressing activation of thrombin in vivo, which comprises introducing into a living body a pharmaceutically effective amount of an N₂ -alkoxynaphthalene-sulfonyl-L-argininamide or the pharmaceutically acceptable salt thereof.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

This invention relates to a group of N² -alkoxynaphthalene-sulfonyl-L-argininamides of the formula (I): ##STR2## wherein R₁ is an alkoxynaphthyl wherein the alkoxy groups have 1-5 (preferably 1-3) carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, tert-butoxy, pentyloxy and the like, and preferred are those naphthyl groups having one or two alkoxy substituents, when two or more alkoxy groups are present, each may be the same or different; R₂ is C₃ -C₁₀ cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl and cyclodecyl, or C₄ -C₁₀ cycloalkylalkyl such as cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl, 2-cyclohexylethyl, cyclooctylmethyl and the like; R₃ is selected from the group consisting of hydrogen, alkyl of 1-10 (preferably 1-6) carbon atoms, such as methyl, ethyl, propyl, butyl, tert-butyl, hexyl, octyl, decyl and the like, C₆ -C₁₀ aryl such as phenyl and naphthyl, preferably phenyl, and aralkyl of 7-12 (preferably 7-10) carbon atoms, such as benzyl, phenethyl and the like; and n is an integer of 1, 2 or 3.

Suitable illustrations of R₁ in the above formula (I) are 5-methoxy-1-naphthyl, 6-methoxy-2-naphthyl, 7-methoxy-2-naphthyl, 4,6-dimethoxy-2-naphthyl, 6,7-dimethoxy-2-naphthyl and 6,7-diethoxy-2-naphthyl.

Suitable R₂ groups in the above formula (I) are cyclopropyl, cyclohexyl, cycloheptyl, and cyclohexylmethyl.

Suitable R₃ groups in the above formula (I) are hydrogen and tert-butyl.

Illustrative of suitable N² -alkoxynaphthalenesulfonyl-L-argininamides of this invention are the following:

N² -(6,7-dimethoxy-2-naphthalenesulfonyl)-L-arginyl-N-cyclohexylmethylglycine

N² -(6,7-dimethoxy-2-naphthalenesulfonyl)-L-arginyl-N-cyclohexylmethylglycine tert-butyl ester

N² -(6,7-dimethoxy-2-naphthalenesulfonyl)-L-arginyl-N-cycloheptylglycine

N² -(6,7-dimethoxy-2-naphthalenesulfonyl)-L-arginyl-N-cycloheptylglycine tert-butyl ester

N² -(4,6-dimethoxy-2-naphthalenesulfonyl)-L-arginyl-N-cyclohexylglycine

N² -(4,6-dimethoxy-2-naphthalenesulfonyl)-L-arginyl-N-cyclohexylglycine tert-butyl ester

N² -(7-methoxy-2-naphthalenesulfonyl)-L-arginyl-N-cyclohexylglycine

N² -(7-methoxy-2-naphthalenesulfonyl)-L-arginyl-N-cyclohexylglycine tert-butyl ester

N² -(6-methoxy-2-naphthalenesulfonyl)-L-arginyl-N-cyclohexylmethylglycine

N² -(6-methoxy-2-naphthalenesulfonyl)-L-arginyl-N-cyclohexylmethylglycine tert-butyl ester

N² -(5-methoxy-1-naphthalenesulfonyl)-L-arginyl-N-cyclohexylmethyl- β-alanine

N² -(5-methoxy-1-naphthalenesulfonyl)-L-arginyl-N-cyclohexylmethyl- β-alanine tert-butyl ester

N² -(6,7-dimethoxy-2-naphthalenesulfonyl)-L-arginyl-N-cyclohexylglycine

N² -(6,7-dimethoxy-2-naphthalenesulfonyl)-L-arginyl-N-cyclohexylglycine tert-butyl ester

N² -(6,7-dimethoxy-2-naphthalenesulfonyl)-L-arginyl-N-cyclohexyl-β-alanine

N² -(6,7-dimethoxy-2-naphthalenesulfonyl)-L-arginyl-N-cyclohexyl-β-alanine tert-butyl ester

N-cyclopropyl-N-(3-carboxypropyl)-N² -(6,7-dimethoxy-2-naphthalenesulfonyl)-L-argininamide

The pharmaceutically acceptable salts of the above compounds are of course also included within the scope of this invention.

These typical compounds are highly potent in their antithrombotic activity.

Of the compounds of this invention, it will be understood that the following compounds are most preferred due to their high level of antithrombotic activity and low level of toxicity.

N² -(6,7-dimethoxy-2-naphthalenesulfonyl)-L-arginyl-N-cyclohexylglycine

N² -(7-methoxy-2-naphthalenesulfonyl)-L-arginyl-N-cyclohexylglycine

N² -(5-methoxy-1-naphthalenesulfonyl)-L-arginyl-N-cyclohexylglycine

The above compounds are intended only to illustrate the variety of structures which can be used in the process of this invention, and the above listing is not to be construed as limiting the scope of the invention.

For the preparation of the compounds of this invention, various methods can be employed depending upon the particular starting materials and/or intermediates involved. Successful preparation of these compounds is possible by way of several synthetic routes which are outlined below.

a. Condensation of an L-argininamide with an alkoxynaphthalenesulfonyl halide

This process may be illustrated as follows: ##STR3##

In the above formulas, R₁, R₂, R₃ and n are as defined herein in above, and X is halogen.

The N² -alkoxynaphthalenesulfonyl-L-argininamide (I) is prepared by the condensation of an L-argininamide (II) with a substantially equimolar amount of an alkoxynaphthalenesulfonyl halide (III), preferably a chloride.

The condensation reaction is generally effected in a suitable reaction-inert solvent in the presence of an excess of a base, such as an organic base (triethylamine, pyridine) or a solution of an inorganic base (sodium hydroxide, potassium carbonate), at a temperature of 0° C. to the boiling temperature of the solvent for a period of 10 minutes to 15 hours.

The preferred solvents for the condensation include benzene-diethyl ether, diethyl ether-water and dioxane-water.

After the reaction is complete, the formed salt is extracted with water, and the solvent is removed by such standard means as evaporation under reduced pressure to give the N² -alkoxynaphthalenesulfonyl-L-argininamide (I), which can be purified by trituration or recrystallization from a suitable solvent, such as diethyl ether-tetrahydrofuran, diethyl ether-methanol and water-methanol, or may be chromatographed on silica gel.

The L-argininamides (II) starting materials required for the condensation reaction can be prepared by protecting the guanidino and α-amino groups of the L-arginine via nitration, acetylation, formylation, phthaloylation, trifluoroacetylation, p-methoxybenzyloxycarbonylation, benzoylation, benzyloxycarbonylation, tert-butoxycarbonylation or tritylation and then condensing the formed N^(G) -substituted-N² -substituted-L-arginine with a corresponding secondary amine by such a conventional process as the acid chloride method, azide method, mixed anhydride method, activated ester method or carbodiimide method, and thereafter selectively removing the protective groups.

b. Removal of the N^(G) -substituent from an N^(G) -substituted-N² -alkoxynaphthalenesulfonyl-L-argininamide

This process may be illustrated as follows: ##STR4##

In the above formulas, R₁, R₂, R₃, X and n are as defined herein above; Y" is a protective group for the amino group, such as benzyloxycarbonyl or tert-butoxycarbonyl; and Y and Y' are hydrogen and protective groups for the guanidino group, such as nitro, tosyl, trityl, oxycarbonyl or the like. At least one of Y and Y' is a protective group for the guanidino group.

The N² -alkoxynaphthalenesulfonyl-L-argininamide (I) is prepared by removing the N^(G) -substituent from an N^(G) -substituted-N² -alkoxynaphthalenesulfonyl-L-argininamide (VIII) by means of acidolysis or hydrogenolysis.

The acidolysis is generally effected by contacting the N^(G) -substituted-N² -alkoxynaphthalenesulfonyl-L-argininamide (VIII) and an excess of an acid such as hydrogen fluoride, hydrogen chloride, hydrogen bromide or trifluoroacetic acid, without a solvent or in a solvent, such as an ether (tetrahydrofuran, dioxane), an alcohol (methanol, ethanol) or acetic acid at a temperature of -10° C. to 100° C., and preferably at room temperature for a period of 30 minutes to 24 hours.

The products are isolated by evaporation of the solvent and the excess acid, or by trituration with a suitable solvent followed by filtration and drying.

Because of the use of the excess acid, the products are generally the acid addition salts of the N² -alkoxynaphthalenesulfonyl-L-argininamides (I), which can be easily converted to a free amide by neutralization.

The removal of the nitro group and the oxycarbonyl group, e.g., benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, is readily accomplished by the hydrogenolysis.

The hydrogenolysis is effected in a reaction-inert solvent, e.g., methanol, ethanol, tetrahydrofuran or dioxane, in the presence of a hydrogen-activating catalyst, e.g., Raney nickel, palladium, or platinum, in a hydrogen atmosphere at a temperature of 0° C. to the boiling temperature of the solvent for a period of 2 hours to 120 hours.

The hydrogen pressure is not critical, and atmospheric pressure is sufficient.

The N² -alkoxynaphthalenesulfonyl-L-argininamides (I) are isolated by filtration of the catalyst followed by evaporation of the solvent.

The N² -alkoxynaphthalenesulfonyl-L-argininamides can be purified in the same manner as described above.

The N^(G) -substituted-N² -alkoxynaphthalenesulfonyl-L-argininamides (VIII) starting materials can be prepared by condensing an N^(G) -substituted-N² -substituted L-arginine (IV) (generally the N² -substituent is a protective group for the amino group, such as benzyloxycarbonyl, tert-butoxycarbonyl, or the like) and a corresponding secondary amine (V) via the azide method, mixed anhydride method, activated ester method, carbodiimido method or the like, selectively removing only the N² -substituent of an N^(G) -substituted-N² -substituted L-argininamide (VI) by means of catalytic hydrogenolysis or acidolysis, and then condensing the thus obtained N^(G) -substituted-L-argininamide (VII) with an alkoxynaphthalenesulfonyl halide (III), preferably a chloride in the presence of a base in a solvent. These reaction conditions are as described above in the condensation of an L-argininamide with an alkoxynaphthalenesulfonyl halide, and the removal of the N^(G) -substitutent from an N^(G) -substituted-N² -alkoxynaphthalenesulfonyl-L-argininamide.

c. Condensation of an N² -alkoxynaphthalenesulfonyl-L-arginyl halide with an amine

This process may be illustrated as follows: ##STR5##

In the above formulas, R₁, R₂, R₃, X and n are as defined herein above.

The N² -alkoxynaphthalenesulfonyl-L-arginamide (I) is prepared by the condensation of an N² -alkoxynaphthalenesulfonyl-L-arginyl halide (IX), preferably a chloride with at least an equimolar amount of a secondary amine (V).

The condensation reaction can be carried out without an added solvent. However, satisfactory results will be obtained with the use of a solvent such as basic solvents (dimethylformamide, dimethylacetamide, etc.) or halogenated solvents (chloroform, dichloromethane, etc.).

The amount of the solvent to be used is not critical and may vary from about 5 to 100 times the weight of the N² -alkoxynaphthalenesulfonyl-L-arginyl halide (IX).

Preferred condensation reaction temperatures are in the range of from -10° C. to room temperature. The reaction time is not critical, but varies with the secondary amine (V) employed. In general, a period of from 5 minutes to 10 hours is operable.

The obtained N² -alkoxynaphthalenesulfonyl-L-argininamide (I) can be isolated and purified in the same manner as described above.

The N² -alkoxynaphthalenesulfonyl-L-arginyl halide (IX) starting materials required for the condensation reaction can be prepared by reacting an N² -alkoxynaphthalenesulfonyl-L-arginine with at least an equimolar amount of a halogenating agent such as thionyl chloride, phosphorous oxychloride, phosphorus trichloride, phosphorous pentachloride or phosphorus tribromide. The halogenation can be carried out with or without an added solvent.

The preferred solvents are chlorinated hydrocarbons such as chloroform and dichloromethane, and ethers such as tetrahydrofuran and dioxane.

The amount of the solvent to be used is not critical and may vary from about 5 to 100 times the weight of the N² -alkoxynaphthalenesulfonyl-L-arginine. Preferred reaction temperatures are in the range of -10° C. to room temperature. The reaction time is not critical, but varies with the halogenating agent and reaction temperature. In general, a period of 15 minutes to 5 hours is operable.

d. Guanidylation of an N² -alkoxynaphthalenesulfonyl-L-ornithinamide or an acid addition salt thereof

This process may be illustrated as follows: ##STR6## In the above formulas, R₁, R₂, R₃ and n are as defined herein above.

The N² -alkoxynaphthalenesulfonyl-L-argininamide (I) is prepared by guanidylating an N² -alkoxynaphthalenesulfonyl-L-ornithinamide (X) with an ordinary guanidylating agent such as an O-alkylisourea, S-alkylisothiourea, 1-guanyl-3,5-dimethylpyrazole or carbodiimide. The preferred guanidylating agents are the O-alkylisourea and the S-alkylisothiourea.

The guanidylation of the N² -alkoxynaphthalenesulfonyl-L-ornithinamide (X) with the O-alkylisourea or S-alkylisothiourea is generally effected in a solvent in the presence of a base at a temperature of from 0° C. to the boiling temperature of the solvent for a period of from 30 minutes to 50 hours.

Examples of the preferred base are triethylamine, pyridine, sodium hydroxide and sodium methoxide.

The base is used in an amount of 0.01 to 0.1 equivalent to the N² -alkoxynaphthalenesulfonyl-L-ornithinamide.

Examples of the preferred solvent are water, water-ethanol and water-dioxane.

After the reaction is complete, the N² -alkoxynaphthalenesulfonyl-L-argininamide (I) is isolated by evaporation of the solvent followed by removal of the excess base and the formed salt by a water wash.

It is well recognized in the art that an ester derivative of the N² -alkoxynaphthalenesulfonyl-L-argininamide (I) wherein R³ is alkyl, aryl or aralkyl, can be prepared from a carboxylic acid derivative of the N² -alkoxynaphthalenesulfonyl-L-argininamide wherein R³ is hydrogen, by the conventional esterification methods well known to those skilled in the art. It is also well recognized in the art that the carboxylic acid derivative can be prepared from the ester derivative by the conventional hydrolysis or acidolysis methods. The conditions under which esterfication, hydrolysis or acidolysis would be carried out will be each apparent to those skilled in the art.

The N² -alkoxynaphthalenesulfonyl-L-argininamide (I) of this invention forms acid addition salts with any of a variety of inorganic or organic acids. Some of the N² -alkoxynaphthalenesulfonyl-L-argininamide containing a free carboxy group, wherein R₃ is hydrogen, forms salts with any of a variety of inorganic and organic bases. The product of the reactions described above can be isolated in the free form or in the form of salts. In addition, the product can be obtained as pharmaceutically acceptable acid addition salts by reacting one of the free bases with an acid, such as hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, acetic, citric, maleic, succinic, lactic, tartaric, gluconic, benzoic, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic acid or the like. In a similar manner, the product can be obtained as pharmaceutically acceptable salts by reacting one of the free carboxylic acids with a base, such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, triethylamine, procaine, dibenzylamine, 1-ephenamine, N,N'-dibenzylethylenediamine, N-ethylpiperidine or the like.

Likewise, treatment of the salts with a base or acid results in a regeneration of the free amide.

As stated above, the N² -alkoxynaphthalenesulfonyl-L-argininamides, and the salts thereof of this invention are characterized by highly specific inhibitory activity against thrombin as well as their substantial lack of toxicity, and therefore, these compounds are useful in the determination of thrombin in blood as diagnostic reagents, and/or for the medical control or prevention of thrombosis.

The antithrombotic activities of the N² -alkoxynaphthalenesulfonyl-L-argininamide of this invention were compared with that of a known antithrombotic agent, N² -(p-tolyl-sulfonyl)-L-arginine methyl ester, by determining the fibrinogen coagulation time. The measurement of the fibrinogen coagulation time was conducted as follows:

An 0.8 ml aliquot of a fibrinogen solution, which had been prepared by dissolving 150 mg of bovine fibrinogen (Cohn fraction I) supplied by Armour Inc. in 40 ml of a borate saline buffer (pH 7.4), was mixed with 0.1 ml of a borate saline buffer, pH 7.4, (control) or a sample solution in the same buffer, and 0.1 ml of a thrombin solution (5 units/ml) supplied by Mochida Pharmaceutical Co., Ltd. was added to the solutions in an ice bath. Immediately after mixing, the reaction mixture was transferred from the ice bath to a bath maintained at 25° C. Coagulation times were taken as the period between the time of transference to the 25° C. bath and the time of the first appearance of fibrin threads. In the cases where no drug samples were added, the coagulation time was 50-55 seconds.

The experimental results are summarized in Table 1. The term "concentration required to prolong the coagulation time by a factor of two" is the concentration of an active ingredient required to prolong the normal coagulation time 50-55 seconds to 100-110 seconds.

The concentration required to prolong the coagulation time by a factor of two for the known antithrombotic agent, N² -(p-tolylsulfonyl)-L-arginine methyl ester, was 1,100 μ m.

The inhibitors are shown in Table 1 by indicating R₁, R₂, R₃ and n in the formula (I) and the addition moiety.

When a solution containing an N² -alkoxynaphthalenesulfonyl-L-argininamide of this invention was administered intravenously into animal bodies, the high antithrombotic activity in the circulating blood was maintained for from one to three hours. The halflife for decay of the anti-thrombotic compounds of this invention in circulating blood was shown to be approximately 60 minutes; the physiological conditions of the host animals (rat, rabbit, dog and chimpanzee) were well maintained. The experimental decrease of fibrinogen in animals caused by infusion of thrombin was satisfactorily controlled by simultaneous infusion of the compounds of this invention.

The acute toxicity values (LD₅₀) determined by intraperitoneal administration of substances of formula (I) in mice (male, 20 g) range from about 1,000 to 10,000 milligrams per kilogram of body weight. Representative LD₅₀ values, for example, for N² -(6,7-dimethoxy-2-naphthalenesulfonyl)-L-arginyl-N-cyclohexylmethylglycine and N² -(6,7-dimethoxy-2-naphthalenesulfonyl)-L-arginyl-N-cyclohexylglycine are above 1,500 milligrams per kilogram each.

On the other hand, LD₅₀ values for N² -dansyl-N-butyl-L-argininamide and N² -dansyl-N-methyl-N-butyl-L-argininamide are 75 and 70 milligrams per kilogram, respectively.

The therapeutic agents of this invention may be administered alone or in combination with pharmaceutically acceptable carriers, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration and standard pharmaceutical practice. For example, the compounds may be injected parenterally, that is, intramuscularly, intravenously or subcutaneously. For parenteral administration, the compounds may be used in the form of sterile solutions containing other solutes, for example, sufficient saline or glucose to make the solution isotonic. The compounds may be administered orally in the form of tablets, capsules, or granules containing suitable excipients such as starch, lactose, white sugar and the like. The compounds may be administered sublingually in the form of troches or lozenges in which each active ingredient is mixed with sugar or corn syrups, flavoring agents and dyes, and then dehydrated sufficiently to make the mixture suitable for pressing into solid form. The compounds may be administered orally in the form of solutions which may contain coloring and flavoring agents.

Physicians will determine the dosage of the present therapeutic agents which will be most suitable, and dosages vary with the mode of administration and the particular compound chosen. In addition, the dosage will vary with the particular patient under treatment.

When the composition is administered orally, a larger quantity of the active agent will be required to produce the same effect as caused with a smaller quantity given parenterally. The therapeutic dosage is generally 10-50 mg/kg of active ingredient parenterally, 10-500 mg/kg orally per day.

Having generally described the invention, a more complete understanding can be obtained by reference to certain specific examples, which are included for purposes of illustration only and are not intended to be limiting unless otherwise specified.

EXAMPLE 1 N² -(6,7-dimethoxy-2-naphthalenesulfonyl)-L-arginyl-N-cyclohexylglycine

To a solution of 3.00 of N^(G) -nitro-N² -(6,7-dimethoxy-2-naphthalenesulfonyl)-L-arginyl-N-cyclohexylglycine benzyl ester in 50 ml of ethanol and 0.5 ml of acetic acid was added 0.5 g of palladium-black and then the mixture was shaken in a hydrogen atmosphere for 100 hours at room temperature. At the end of this period, the ethanol solution was filtred to remove the catalyst and evaporated to dryness. The residue was washed several times with dry diethyl ether and chromatographed on 80 ml of Daiaion SK 102 ion exchange resin (200-300 mesh, H⁺ form, manufactured by Mitsubishi Chemical Industries Limited) packed in water, washed with water and eluted with 3% ammonium hydroxide solution. The fraction eluted from 3% ammonium hydroxide solution was evaporated to dryness to give 1.65 g (68%) of N² -(6,7-dimethoxy-2-naphthalenesulfonyl)-L-arginyl-N-cyclohexylglycine as an amorphous solid.

IR (KBr): 3,400-3,200 (broad), 1,600 cm⁻ ¹

Analysis - Calcd. for C₂₆ H₃₇ N₅ O₇ S (percent): C, 55.40; H, 6.62; N, 12.43 found (percent): C, 55.30; H, 6.28; N, 12.11

EXAMPLE 2 N² -(5-methoxy-1-naphthalenesulfonyl)-L-arginyl-N-cyclohexylmethyl- β -alanine

A. N-cyclohexylmethyl- β -alanine tert-butyl ester

To 33.76 g of cyclohexylmethylamine was added with stirring 15.96 g of tert-butyl β -chloropropionate over a period of 30 minutes, while maintaining the temperature at 30°-70° C. The reaction mixture was held at 70° C. for an additional one hour. At the end of this period, the reaction mixture was taken up in 40 ml of 2N NaOH solution and 50 ml of benzene, transferred into a separatory funnel and well shaken. The benzene solution was separated, washed with water, dried over anhydrous sodium sulfate and filtered. After evaporation of benzene, the residue was distilled under reduced pressure to give 21.0 g (89 percent) of N-cyclohexylmethyl- β -alanine tert-butyl ester, B.P. 156° C./15 mmHg.

Analysis -- Calcd. for C₁₄ H₂₂ NO₂ (percent): C, 71.15; H, 9.38; N, 5.93 Found (percent): C, 70.89; H, 9.37; N, 5.78.

B. N² -(5-methoxy-1-naphthalenesulfonyl)-L-arginyl chloride hydro chloride

A suspension of 2.00 g of N² -(5-methoxy-1-naphthalenesulfonyl)-L-arginine in 20 ml of thionyl chloride was stirred for 2 hours at room temperature. Addition of cold dry diethyl ether resulted in a precipitate which was collected by filtration and washed several times with dry diethyl ether to give N² -(5-methoxy-1-naphthalenesulfonyl)-L-arginyl chloride hydrochloride.

C. N² -(5-methoxy-1-naphthalenesulfonyl)-L-arginyl-N-cyclohexylmethyl- β -alanine tert-butyl ester

To a stirred solution of 3.67 g of N-cyclohexylmethyl- β -alanine tert-butyl ester in 20 ml of chloroform was carefully added N² -(5-methoxy-1-naphthalenesulfonyl)-L-arginyl chloride hydrochloride obtained above. The reaction mixture was allowed to stand at room temperature for one hour. At the end of this period, the reaction mixture was washed twice with 20 ml of saturated sodium chloride solution and evaporated to dryness.

Addition of 100 ml of diethyl ether to the residue resulted in a precipitate which was separated by decantation and purified by reprecipitation with ethanol-diethyl ether to give 2.60 g (83 percent) of N² -(5-methoxy-1-naphthalenesulfonyl)-L-argininyl-N-cyclohexylmethyl- β -alanine tert-butyl ester.

For analysis of the product, a portion of the product was converted to the flavianate, M.P. 152°-155° C.

IR (KBr): 3,390, 3,205, 1,730 cm⁻

Analysis -- Calcd. for C₃₁ H₄₇ N₅ O₆ S.C₁₀ H₆ N₂ O₈ S (percent):

C, 52.83; H, 5.73; N, 10.52

Found (percent): C, 52.53; H, 5.72; N, 10.29

D. N² -(5-methoxy-1-naphthalenesulfonyl)-L-arginyl-N-cyclohexylmethyl- β -alanine

To a solution of 2.00 g of N² -(5-methoxy-1-naphthalenesulfonyl)-L-arginyl-N-cyclohexylmethyl- β -alanine tert-butyl ester in 20 ml of chloroform was added 50 ml of 15% HCl-ethyl acetate. The reaction mixture was stirred for 5 hours at room temperature. At the end of this period, the reaction mixture was evaporated to dryness. The residue was washed several times with dry diethyl ether and chromatographed on 80 ml of Daiaion SK 102 ion exchange resin (200-300 mesh, H⁺ form, manufactured by Mitsubishi Chemical Industries Limited) packed in water, washed with water and eluted with 3% ammonium hydroxide solution.

The fraction eluted from 3% ammonium hydroxide solution was evaporated to dryness to give 1.29 g (71 percent) of N² -(5-methoxy-1-naphthalenesulfonyl)-L-arginyl-N-cyclohexylmethyl- β -alanine as an amorphous solid.

IR (KBr): 3,370, 1,630 cm⁻ ¹

Analysis -- Calcd. for C₂₇ H₃₉ N₅ O₆ S (percent): C, 57.73; H, 7.00; N, 12.47

Found (percent): C, 57.51; H, 7.23; N, 12.28

Various other N² -alkoxynaphthalenesulfonyl-L-arginamides or acid addition salts thereof were synthesized in accordance with the procedure of the above examples, and the test results are summarized in Table 1.

    TABLE 1  COMPOUND      Sample       ##STR7##       Concentration required toprolong thecoagulationtime by afactor of two       Prepara-tionprocess m.p. ElementaryAnalysisUpper:CalculatedLower:Found      I.R. (KBr) Number R.sub.1 R.sub.2 R.sub.3 n Addition moiety (μM)      (Ex.No.) (° C.) C H N (cm.sup..sup.-1)  1       ##STR8##       ##STR9##       C(CH.sub.3).sub.3 1       ##STR10##       2 165-168(dec) 51.9451.50 5.64 5.41 10.3410.10 3,3903,2201,740 2       ##STR11##       " H 1 -- 2 powder 56.1356.00 6.816.73 12.1212.01 3,350 (broad)1,640 3       ##STR12##       ##STR13##       C(CH.sub.3).sub.3 1       ##STR14##       2 178-181(dec) 51.9452.24 5.645.60 10.3410.28 3,4003,2001,735 4       ##STR15##       " H 1 -- 2 powder 56.1356.28 6.816.59 12.1212.31 3,350 (broad)1,640 5       ##STR16##       ##STR17##       C(CH.sub.3).sub.3 1       ##STR18##       2 162-165(dec) 51.4351.28 5.505.21 10.5010.21 3,3703,2001,730 6       ##STR19##       " H 1 -- 2 powder 55.4055.28 6.626.32 12.4312.03 3,300 (broad)1,610      (broad) 7       ##STR20##       " C(CH.sub.3).sub.3 1       ##STR21##       2 158-160(dec) 52.7552.56 5.565.43 11.0410.97 3,4053,2201,740

    TABLE 2  Compound      Sample       ##STR22##       Concentrationrequired toprolong thecoagulationtime by afactor of two      Prepara-tionprocess m.p. Elementary AnalysisUpper: CalculatedLower:      Found IR (KBr) No. R.sub.1 R.sub.2 R.sub.3 n Addition moiety (μ M)      (Ex. No.) (° C.) C H N (cm.sup.-1)               8       ##STR23##       ##STR24##       H 1 --  2 powder 56.2656.01 6.616.49 13.1313.21 3,320(broad)1,640  9       ##STR25##       ##STR26##       C(CH.sub.3).sub.3 1       ##STR27##        2 160-163(dec) 52.3352.03 5.605.30 10.6810.28 3,4003,2101,730  10       ##STR28##       " H 1 --  2 powder 57.0257.39 6.816.21 12.7912.38 3,350(broad)1,620  11       ##STR29##       " C(CH.sub.3).sub.3 2       ##STR30##        2 152-155(dec) 52.8352.53 5.735.72 10.5210.29 3,3903,2051,730  12       ##STR31##       " H 2 --  2 powder 57.7357.51 7.007.23 12.4712.28 3,3701,630  13       ##STR32##       ##STR33##       C(CH.sub.3).sub.3 1       ##STR34##        2 170-172(dec) 51.4351.09 5.505.45 10.5010.28 3,3803,2201,740  14       ##STR35##       " H 1 -- 5 1 powder 55.4055.30 6.626.28 12.4312.11 3,400-3,200(broad)1,6      00       15      ##STR36##       " C(CH.sub.3).sub.3 2       ##STR37##        2 155-158(dec) 51.9452.29 5.645.63 10.3410.00 3,3803,2001,730  16       ##STR38##       " H 2 --  1 powder 56.1356.40 6.816.61 12.1212.00 3,200-3,400(broad)1,60       17 "      ##STR39##       H 3 --  1 " 54.6354.40 6.426.30 12.7412.50 3,200-3,400(broad)1,600

The following compounds are prepared in a similar manner.

N² -(5-methoxy-1-naphthalenesulfonyl)-L-arginyl-N-cyclohexylglycine

N² -(7-methoxy-2-naphthalenesulfonyl)-L-arginyl-N-cyclohexylpropylglycine

N² -(7-methoxy-2-naphthalenesulfonyl)-L-arginyl-N-cyclohexyl- β -alanine

N² -(6,7-diethoxy-2-naphthalanesulfonyl)-L-arginyl-N-cyclohexylglycine

4-N-[N² -(6,7-dimethoxy-2-naphthalenesulfonyl)-L-arginyl[-N-cyclohexylaminobutyric acid

EXAMPLE 3

Tablets suitable for oral administration

Tablets containing the ingredients indicated below may be prepared by conventional techniques.

    ______________________________________                                                                   Amount per                                           Ingredient                tablet (mg)                                          ______________________________________                                         N.sup.2 -(6,7-dimethoxy-2-naphthalenesulfonyl)-                                                             250                                               L-arginyl-N-cyclohexylglycine                                                  Lactose                      140                                               Corn starch                   35                                               Talcum                        20                                               Magnesium stearate            5                                                Total                        450 mg                                            ______________________________________                                    

EXAMPLE 4 Capsules for oral administration

Capsules of the below were made up by thoroughly mixing together batches of the ingredients and filling hard gelatin capsules with the mixture.

    ______________________________________                                                                   Amount per                                           Ingredient                capsule (mg)                                         ______________________________________                                         N.sup.2 -(6,7-dimethoxy-2-naphthalenesulfonyl)-                                                             250                                               L-arginyl-N-cyclohexylglycine                                                  Lactose                      250                                               Total                        500 mg                                            ______________________________________                                    

EXAMPLE 5 Sterile solution for infusion

The following ingredients are dissolved in water for intravenous perfusion and the resulting solution is then sterilized.

    ______________________________________                                         Ingredients               Amount (g)                                           ______________________________________                                         N.sup.2 -(6,7-dimethoxy-2-naphthalenesulfonyl)-                                                          25                                                   L-arginyl-N-cyclohexylglycine                                                  Buffer system             As desired                                           Glucose                   25                                                   Distilled water           500                                                  ______________________________________                                    

Having now fully described the invention, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the invention as set forth herein. 

What is claimed as new and intended to be covered by letters patent is:
 1. N² -alkoxynaphthalenesulfonyl-L-argininamides having the formula (I): ##STR40## or the pharmaceutically acceptable salts thereof wherein R₁ is naphthyl substituted with at least one C₁ -C₅ alkoxy; R₂ is C₃ -C₁₀ cycloalkyl or C₄ -C₁₀ cycloalkylalkyl; R₃ is selected from the group consisting of hydrogen, C₁ -C₁₀ alkyl, C₆ -C₁₀ aryl and C₇ -C₁₂ aralkyl; and n is an integer of 1, 2 or
 3. 2. The compound of claim 1, wherein R₁ is naphthyl substituted with one or two C₁ -C₃ alkoxy; R₂ is C₃ -C₁₀ cycloalkyl or C₄ -C₁₀ cycloalkylalkyl; R₃ is selected from the group consisting of hydrogen, C₁ -C₆ alkyl, phenyl and C₇ -C₁₀ aralkyl; and n is an integer of 1, 2 or
 3. 3. The compound of claim 2, wherein R₁ is selected from the group consisting of 5-methoxy-1-naphthyl, 6-methoxy-2-naphthyl, 7-methoxy-2-naphthyl, 4,6-dimethoxy-2-naphthyl, 6,7-dimethoxy-2-naphthyl and 6,7-diethoxy-2-naphthyl; R₂ is selected from the group consisting of cyclopropyl, cyclohexyl, cycloheptyl and cyclohexylmethyl; and R is hydrogen or tert-butyl.
 4. A compound of claim 3, which is N² -(6,7-dimethoxy-2-naphthalenesulfonyl)-L-arginyl-N-cyclohexylglycine
 5. A compound of claim 3, which is N² -(7-methoxy-2-naphthalenesulfonyl)-L-arginyl-N-cyclohexylglycine
 6. A compound of claim 3, which is N² -(5-methoxy-1-naphthalenesulfonyl)-L-arginyl-N-cyclohexylglycine
 7. A method for inhibiting activity and suppressing activation of thrombin in vivo, which comprises administering to a patient a pharmaceutically effective amount of an N² -alkoxynaphthalenesulfonyl-L-argininamide having the formula (I): ##STR41## or a pharmaceutically acceptable salt thereof wherein R₁ is naphthyl substituted with at least one C₁ -C₅ alkoxy; R₂ is C₃ -C₁₀ cycloalkyl or C₄ -C₁₀ cycloalkylalkyl; R₃ is selected from the group consisting of hydrogen, C₁ -C₁₀ alkyl, C₆ -C₁₀ aryl and C₇ -C₁₂ aralkyl; and n is an integer of 1, 2 or
 3. 